Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce
European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr
The European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of immune-related conditions and sometimes fatal problems with the heart a
Bayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 million alleging that blockbuster blood thinner Xarelto caused unstoppable and someti
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.